Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) slipped over -10.29% at $2.44. Synergy Pharmaceuticals Inc. has 245.63 million shares outstanding, and in the last trade has seen ATR around 0.2. The volume of SGYP witnessed a shift from 23.98 million shares, based on a 50-day average, to 5.65 million shares.

In the most updated research from a number of analysts on Wall Street, the company gets 5 Buys and 1 Sell among 6 analysts. Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) hasconsensus analyst target price is $7.9. That gives us a street projected return of 223.77%. If the published price targets set by Synergy Pharmaceuticals Inc. analysts have any power to influence the stock’s share price, the highest price target set for SGYP is $13.

On a similar note, analysts expect EPS of -$0.22 in December 2017 quarter and -$0.15 in March 2018 quarter, representing -29.03% and -50% growth, respectively. They expect this year’s earnings to fall -6.61% year-over-year to -$1.13, followed by -55.75% decline in the next year to -$0.5.

Shares of Pfizer Inc. (NYSE:PFE) traded up 0.34% in the last session while performance was up 35.3% in the last five days. The stock’s last price was lower from the average trading price of 50 days recorded at $35.58 while enlarging the period to 200 trading days, the average price was $33.93. Currently, 5.96 billion total shares are owned by the public and among those 5.92 billion shares have been available to trade. The percentage of shares being held by the company management was 0.03% while institutional stake was 71.6%.

Pfizer Inc. (PFE) has risen 15.7% since then. But since then, those gains have faded by -4.02%. PFE has lost -2.86% in the 1-month period.

Synergy Pharmaceuticals Inc. has a beta of 0.99, offering the possibility of a higher rate of return, but also posing more risk. The portion of a company’s profit allocated to each outstanding share of common stock was $1.63 a share in the trailing twelve months. It last reported revenues of $13.17 billion and EPS of $0.67 for the September 2017, representing 1% top-line growth and 0.61 EPS growth.

Looking forward, the company’s quarterly earnings are expected to come at $0.55 in the three months through December 2017 and $0.69 in the quarter ending March 2018, reflecting 17.02% and 0% growth, respectively. For the full year, analysts expect earnings to jump 7.92% yoy to $2.59. Next year this growth will reach 5.79% to attain $2.74.